MaxCyte, Inc. (LON:MXCT - Get Free Report)'s stock price crossed below its 200-day moving average during trading on Wednesday . The stock has a 200-day moving average of GBX 288.04 ($3.83) and traded as low as GBX 210 ($2.79). MaxCyte shares last traded at GBX 212 ($2.82), with a volume of 20,024 shares changing hands.
MaxCyte Price Performance
The company has a quick ratio of 14.38, a current ratio of 9.81 and a debt-to-equity ratio of 8.59. The business has a fifty day moving average of GBX 224.13 and a 200 day moving average of GBX 286.49. The firm has a market cap of £270.61 million, a P/E ratio of -7.51 and a beta of 1.13.
About MaxCyte
(
Get Free Report)
MaxCyte is a leading cell-engineering company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell-based therapeutics and to support innovative, cell-based research. MaxCyte brings best-in-class technology paired with ongoing support designed to facilitate complex engineering of a wide variety of cells and payloads, with the aim of advancing new treatment options for patients.
Read More
Before you consider MaxCyte, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and MaxCyte wasn't on the list.
While MaxCyte currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
